Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Short-term Investments (2022 - 2025)

Historic Short-term Investments for Inhibikase Therapeutics (IKT) over the last 4 years, with Q3 2025 value amounting to $39.1 million.

  • Inhibikase Therapeutics' Short-term Investments rose 157591.09% to $39.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.1 million, marking a year-over-year increase of 157591.09%. This contributed to the annual value of $41.1 million for FY2024, which is 90450.76% up from last year.
  • Inhibikase Therapeutics' Short-term Investments amounted to $39.1 million in Q3 2025, which was up 157591.09% from $9.9 million recorded in Q2 2025.
  • In the past 5 years, Inhibikase Therapeutics' Short-term Investments registered a high of $41.1 million during Q4 2024, and its lowest value of $2.0 million during Q3 2023.
  • Moreover, its 4-year median value for Short-term Investments was $15.9 million (2022), whereas its average is $16.0 million.
  • As far as peak fluctuations go, Inhibikase Therapeutics' Short-term Investments tumbled by 9050.58% in 2023, and later skyrocketed by 157591.09% in 2025.
  • Quarter analysis of 4 years shows Inhibikase Therapeutics' Short-term Investments stood at $15.9 million in 2022, then plummeted by 74.23% to $4.1 million in 2023, then surged by 904.51% to $41.1 million in 2024, then fell by 4.87% to $39.1 million in 2025.
  • Its Short-term Investments stands at $39.1 million for Q3 2025, versus $9.9 million for Q2 2025 and $19.7 million for Q1 2025.